 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...127128129130131132133134135136137...143144» |
- ||| elgemtumab (LJM-716) / Novartis, MorphoSys
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients (clinicaltrials.gov) - Jun 27, 2014
P1/2, N=128, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jun 2014 --> Mar 2015 | Trial primary completion date: Dec 2016 --> Aug 2017
- |||| duligotuzumab (MEHD7945A) / Roche
Enrollment open, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jun 27, 2014
P2, N=120, Recruiting, Sponsor: Genentech
Initiation date: Jun 2014 --> Mar 2015 | Trial primary completion date: Dec 2016 --> Aug 2017 Active, not recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=98, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Recruiting Trial primary completion date: Jan 2014 --> Jan 2016
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=98, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jan 2014 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Jan 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: An Observational Study of Erbitux (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=146, Terminated, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Jan 2016 Completed --> Terminated; This study was terminated due to low recruitment
- adjuvant CpG 1018 / Dynavax
Trial termination, Metastases: A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 18, 2014
P1, N=15, Terminated, Sponsor: Dynavax Technologies Corporation
Completed --> Terminated; This study was terminated due to low recruitment Active, not recruiting --> Terminated; Administrative reasons
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: A Trial of Chemo & Radiation Therapy for Pancreatic Cancer (clinicaltrials.gov) - Jun 17, 2014
P2, N=8, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Terminated; Administrative reasons Trial primary completion date: Dec 2013 --> Dec 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE) (clinicaltrials.gov) - Jun 17, 2014
P2, N=4, Terminated, Sponsor: University of Michigan Cancer Center
Trial primary completion date: Dec 2013 --> Dec 2014 Completed --> Terminated; The study was discontinued prematurely due to early stopping rules.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE) (clinicaltrials.gov) - Jun 17, 2014
P2, N=4, Terminated, Sponsor: University of Michigan Cancer Center
Completed --> Terminated; The study was discontinued prematurely due to early stopping rules. N=100 --> 4
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 12, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
N=100 --> 4 Trial primary completion date: Jul 2008 --> Oct 2007
- | Nimoral (nimorazole) / Norgine, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) (clinicaltrials.gov) - Jun 12, 2014
P3, N=470, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Trial primary completion date: Jul 2008 --> Oct 2007 Initiation date: Dec 2013 --> May 2014
- | Nimoral (nimorazole) / Norgine, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) (clinicaltrials.gov) - Jun 12, 2014
P3, N=470, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Initiation date: Dec 2013 --> May 2014 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: eSCOUT: Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy (clinicaltrials.gov) - Jun 12, 2014
P2, N=47, Completed, Sponsor: Christie Hospital NHS Foundation Trust
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 9, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Pan tumor: An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status (clinicaltrials.gov) - Jun 8, 2014
P1, N=102, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Trial primary completion date: May 2015 --> May 2016
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: COMMENCE: A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck (clinicaltrials.gov) - Jun 5, 2014
P1/2, N=120, Recruiting, Sponsor: Radboud University
Trial primary completion date: May 2015 --> May 2016 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Jun 4, 2014
P2, N=50, Recruiting, Sponsor: Shruti Jolly
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2014 --> Feb 2015
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) (clinicaltrials.gov) - Jun 4, 2014
P2, N=289, Completed, Sponsor: Merck KGaA
Trial primary completion date: Feb 2014 --> Feb 2015 Trial primary completion date: Oct 2012 --> Apr 2014
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) (clinicaltrials.gov) - Jun 4, 2014
P2, N=289, Completed, Sponsor: Merck KGaA
Trial primary completion date: Oct 2012 --> Apr 2014 Active, not recruiting --> Completed
- || duligotuzumab (MEHD7945A) / Roche
Trial primary completion date, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jun 2, 2014
P2, N=135, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Jun 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab (clinicaltrials.gov) - May 27, 2014
P1, N=140, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2015 --> Jun 2015 Trial primary completion date: Jul 2019 --> May 2014
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab (clinicaltrials.gov) - May 27, 2014
P1, N=140, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2019 --> May 2014 N=198 --> 140
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab (clinicaltrials.gov) - May 27, 2014
P1, N=140, Completed, Sponsor: M.D. Anderson Cancer Center
N=198 --> 140 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Sirolimus and Cetuximab in Advanced Malignancies (clinicaltrials.gov) - May 27, 2014
P1, N=165, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> May 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Sirolimus and Cetuximab in Advanced Malignancies (clinicaltrials.gov) - May 27, 2014
P1, N=165, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2016 --> May 2014 N=137 --> 165
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Sirolimus and Cetuximab in Advanced Malignancies (clinicaltrials.gov) - May 27, 2014
P1, N=165, Completed, Sponsor: M.D. Anderson Cancer Center
N=137 --> 165 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date, Metastases: Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab (clinicaltrials.gov) - May 20, 2014
P2, N=80, Recruiting, Sponsor: Academic and Community Cancer Research United
Recruiting --> Completed Trial primary completion date: Apr 2015 --> Aug 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN (clinicaltrials.gov) - May 20, 2014
P1/2, N=9, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Apr 2015 --> Aug 2014 N=98 --> 9
- Enrollment open, Metastases: MetAction: N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (clinicaltrials.gov) - May 20, 2014
P2, N=50, Recruiting, Sponsor: Oslo University Hospital
N=98 --> 9 Not yet recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Pre-op Rectal ChemoRad +/- Cetuximab (clinicaltrials.gov) - May 20, 2014
P2, N=130, Active, not recruiting, Sponsor: US Oncology Research
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2014 --> Feb 2014
- || dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial primary completion date, Combination therapy, Metastases: A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) (clinicaltrials.gov) - May 20, 2014
P2a, N=70, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Feb 2014 --> Feb 2014 Trial primary completion date: Jul 2014 --> Aug 2014
- || dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial completion date, Combination therapy, Metastases: A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) (clinicaltrials.gov) - May 20, 2014
P2a, N=70, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jul 2014 --> Aug 2014 Trial completion date: Jul 2014 --> Aug 2014
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - May 19, 2014
P2, N=75, Active, not recruiting, Sponsor: University of Southern California
Trial completion date: Jul 2014 --> Aug 2014 Trial primary completion date: Jan 2014 --> Jan 2015
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - May 19, 2014
P2, N=75, Active, not recruiting, Sponsor: University of Southern California
Trial primary completion date: Jan 2014 --> Jan 2015 Trial completion date: Jan 2016 --> Dec 2015
- ||||| elgemtumab (LJM-716) / Novartis, MorphoSys
New P1/2 trial, Combination therapy, Metastases: Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients (clinicaltrials.gov) - May 19, 2014
P1/2, N=128, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion, Combination therapy: Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - May 19, 2014
P1, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2016 --> Dec 2015 Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Docetaxel+Oxali+/-Cetux Met Gastric/GEJ (clinicaltrials.gov) - May 18, 2014
P2, N=150, Completed, Sponsor: US Oncology Research
Active, not recruiting --> Completed Trial primary completion date: Mar 2009 --> Apr 2012
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: Docetaxel+Oxali+/-Cetux Met Gastric/GEJ (clinicaltrials.gov) - May 18, 2014
P2, N=150, Completed, Sponsor: US Oncology Research
Trial primary completion date: Mar 2009 --> Apr 2012 Trial completion date: Sep 2011 --> Apr 2012
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 18, 2014
P1/2, N=35, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial completion date: Sep 2011 --> Apr 2012 Recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Docetaxel+Oxali+/-Cetux Met Gastric/GEJ (clinicaltrials.gov) - May 18, 2014
P2, N=150, Completed, Sponsor: US Oncology Research
Recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors (clinicaltrials.gov) - May 18, 2014
P1, N=22, Recruiting, Sponsor: Georgetown University
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Dec 2014
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: CA225200: PhII ICb With/Without Erbitux in MBC Pts (clinicaltrials.gov) - May 18, 2014
P2, N=154, Active, not recruiting, Sponsor: US Oncology Research
Trial primary completion date: May 2014 --> Dec 2014 Trial primary completion date: Jun 2013 --> Jun 2014
- New P2 trial, Metastases: MetAction: N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (clinicaltrials.gov) - May 18, 2014
P2, N=50, Not yet recruiting, Sponsor: Oslo University Hospital
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date: A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors (clinicaltrials.gov) - May 18, 2014
P1, N=22, Recruiting, Sponsor: Georgetown University
Trial primary completion date: Jun 2013 --> Jun 2014 Initiation date: May 2013 --> Sep 2013
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - May 13, 2014
P2, N=143, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: May 2013 --> Sep 2013 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Surgery, Metastases: EMR 622022237: Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (clinicaltrials.gov) - May 11, 2014
P2, N=145, Active, not recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Apr 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - May 11, 2014
P2, N=50, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial primary completion date: Dec 2016 --> Apr 2015 Trial primary completion date: Oct 2013 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Surgery, Metastases: EMR 622022237: Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (clinicaltrials.gov) - May 11, 2014
P2, N=145, Active, not recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Oct 2013 --> Dec 2016 Trial completion date: Feb 2017 --> Oct 2019
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date: Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - May 11, 2014
P2, N=50, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Feb 2017 --> Oct 2019 Trial completion date: Oct 2013 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Surgery, Metastases: EMR 622022237: Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (clinicaltrials.gov) - May 11, 2014
P2, N=145, Active, not recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial completion date: Oct 2013 --> Dec 2016 N=115 --> 145